Talaris Therapeutics
Louisville
About Talaris Therapeutics
Talaris Therapeutics is a operator of a biotechnology company engaged in the development of innovative cellular therapies. The company's proprietary allogeneic cell therapy product has shown to induce tolerance in recipients of solid organ transplants from unmatched and unrelated donors, enabling living donor kidney transplant recipients to wean completely off immunosuppression one year after transplant.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Delisted
- Employees: 101 – 250
- Estimated revenue: $10K – $50K
- Total funding: $215.0M
- Funding stage: M&A
- Last round: Series B (Oct 2020)
- Ticker: nasdaq:TALS
- Website: talaristx.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Health Care, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/talaris-therapeutics-28366 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.